CD34 and acute myeloid leukemia: Here, we demonstrate that a combined flow cytometry-based redox metabolic approach in parallel on AML CD34+ (CD38low/-) cells and EVAML is readily applicable in fresh blood and might be exploited to reveal critical metabolic vulnerabilities for prognostic purposes.